Skip to main content
Equibles

ANURAS · Anupam Rasayan India Limited

Use ANURAS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANURAS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,302.25 INR +101.50 (+8.45%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 48.4K Avg daily vol (3M) 13.15K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close1,302.25 INR Open1,209.55 INR Day1,204.55–1,305.00 INR 52W close1,072.55–1,376.85 INR Avg vol 30d10K Last earningsNov 6, 2026 DataMar 2021–Nov 2026

Latest documents

2026
Nov 6
Earnings call
Q2 FY27 EBITDA rises 41% after Bliss acquisition completes

Anupam Rasayan India Limited completed the Bliss GVS Pharma Limited acquisition on September 28, 2026, holding approximately 50.07%. Q2 FY27 total income was INR821 crores and EBITDA INR202 crores, up 11% and 41% year-on-year, with a 25% margin.

4 source passages
Ladies and gentlemen, good day, and welcome to the Q2 and H1 FY27 Earnings Call for Anupam Rasayan India Limited. Completion of Bliss GVS Pharma acquisition as on September 28, 2026, marks an important milestone in our journey towards building an integrated pharmaceutical platform. Anupam Rasayan now holds approximately 50.07% of the equity capital of Bliss GVS Pharma. Total income for the quarter stood at INR821 crores compared to INR739 crores in the corresponding quarter last year, registering a strong growth of 11% year-on-year. EBITDA for the quarter stood at INR202 crores compared to INR144 crores in Q2FY26, representing a growth of 41% year-on-year. Our consolidated EBITDA margin improved to 25% in Q2 FY27 compared to 19% in the corresponding quarter last year, while H1 margins improved from 26% from 22%. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲32% 3.90B INR 281.92M INR '25 Q3 ▲24.7% 5.00B INR 445.67M INR '25 Q4 ▲91.1% 4.86B INR 340.36M INR '26 Q1 ▲148.8% 7.31B INR 443.93M INR '26 Q2 ▲31.3% 5.12B INR 490.41M INR '26 Q3 ▲27.1% 6.36B INR 426.50M INR '26 Q4 ▲34.8% 6.55B INR 386.39M INR '27 Q1 LATEST ▲10.2% 8.06B INR 500.34M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 1,072.55 INR Now 1,302.25 INR · 75% Range high 1,376.85 INR
vs 200-day avg +4% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:ANURAS +12.2% +12.3% -3.6% +14.1% -1.3%

Exchange listing

Market
XBOM
Ticker
ANURAS
ISIN
INE930P01018
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.anupamrasayan.com/
Investor relations
https://www.anupamrasayan.com/investors/results-reports

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-09-18 1.50 INR
2025-07-21 0.75 INR
2024-09-17 0.75 INR
2023-11-20 0.50 INR
2023-05-15 1.50 INR
2023-02-08 0.60 INR
2022-09-02 1.00 INR
2022-08-03 0.40 INR
2021-11-17 0.50 INR
2021-09-15 0.50 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-06 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-14 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-25 Transcript
    Earnings Call for the Quarter Ended March 31, 2026